Lunit Inc 2025 SR
The report highlights Lunit's sustainability achievements and strategic direction for the fiscal year 2025, guided by its vision to conquer cancer through AI. Key milestones include the successful integration of Volpara Health Technologies (renamed Lunit International) and partnerships with global pharmaceutical companies like AstraZeneca and Daiichi-Sankyo. The company advanced its environmental commitment by declaring its SBTi near-term targets and establishing a Scope 1, 2, and 3 greenhouse gas inventory. Additionally, Lunit expanded its global healthcare accessibility through B2G and ODA projects, notably in Saudi Arabia and Peru.
Company: Lunit Inc
Sector: Media & publishing
Country: South Korea
Year: 2025
Type: SR
Pages: 88
Back to company
Lunit Inc
Sustainability Report
The report highlights Lunit's sustainability achievements and strategic direction for the fiscal year 2025, guided by its vision to conquer cancer through AI. Key milestones include the successful integration of Volpara Health Technologies (renamed Lunit International) and partnerships with global pharmaceutical companies like AstraZeneca and Daiichi-Sankyo. The company advanced its environmental commitment by declaring its SBTi near-term targets and establishing a Scope 1, 2, and 3 greenhouse gas inventory. Additionally, Lunit expanded its global healthcare accessibility through B2G and ODA projects, notably in Saudi Arabia and Peru.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees